|
||
| |||||||
|
Borean Pharma Granted United States Patent for Lead Therapeutic Candidate for Atherosclerosis Aarhus, Denmark, May 31, 2005 - Borean Pharma A/S, the biopharmaceutical and protein engineering company, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 6,897,039 for the Company’s atherosclerosis drug candidate, Trimeric Apolipoprotein A-I, which is in preclinical development. The Borean atherosclerosis drug candidate is a trimerised version of the naturally occurring protein, Apolipoprotein A-I (ApoA-I). ApoA-I is the major protein component of High Density Lipoprotein (HDL), so-called "good cholesterol". Plasma levels of HDL and ApoA-I have been found to be inversely correlated with the incidence of atherosclerosis. Trimeric Apo A-I has been shown to stabilise and inhibit plaque formation in mice arteries more effectively than the naturally occurring monomeric form. Borean Pharma initially developed this trimeric ApoA-I protein in collaboration with Proteopharma. Proteopharma was acquired by Borean Pharma in February 2004. Recently, a Phase II clinical trial demonstrated that a dimeric variant of Apolipoprotein A-I, ApoA-I Milano, reduced the fatty arterial plaque that triggers most heart attacks by an average of 4.2%. Dr. Johanna Holldack, CEO Borean Pharma commented: “Once again the granting of this patent adds to the broad patent portfolio that Borean is building up around its protein therapeutics. Specifically, this patent refers to one of our lead therapeutic candidates in an area of significant clinical need.” – ends – About Borean Pharma Borean Pharma was established with the objective to develop a new generation of pharmaceutical protein products. The company's competitive advantage lies in its proprietary technology, enabling it to develop a new generation of highly efficacious compounds and antibody analogues that can be produced in E.coli. The ease of production addresses a major shortcoming of monoclonal antibodies. Borean Pharma believes that it can unleash the true potential of biopharmaceuticals by providing efficacious and cost-effective protein-based antibody analogues. For further information please visit the website at www.boreanpharma.com Contact:
Dr. Johanna Holldack
Dr. Douglas
Pretsell |
|
| ||||||||